Casi expands TNBC testing in China; CFDA nod for phase II trials
By Cornelia Zou
Wednesday, July 23, 2014
HONG KONG – A Chinese-focused U.S. biopharma company got the green light from the CFDA to carry out phase II trials for a new cancer drug.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.